News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Daily News PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis Michael O'Riordan December 14, 2017
News Conference News AHA 2017 RE-DUAL PCI Findings Consistent Across Key Subgroups Todd Neale November 16, 2017
News Conference News AHA 2017 Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation Michael O'Riordan November 13, 2017
News Conference News TCT 2017 No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy Michael O'Riordan October 30, 2017
News Daily News No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib Michael O'Riordan September 29, 2017
News Conference News ESC 2017 ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach Todd Neale September 01, 2017
News Conference News ESC 2017 Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI Todd Neale August 27, 2017
News Daily News How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis Shelley Wood August 15, 2017
News Daily News Study Suggests VKA Monotherapy Sufficient in Patients With A-fib but No CAD Yael L. Maxwell June 20, 2017
Presentation TVT 2017 Managing AS Patients With Atrial Fibrillation After TAVR Pharmacotherapy Considerations and LAAC Possibilities Presenter: Samir R. Kapadia June 16, 2017
News Daily News Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women Todd Neale May 11, 2017
News Daily News More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds Todd Neale May 05, 2017
News Daily News Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions Todd Neale March 28, 2017
News Daily News Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA Michael O'Riordan March 15, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017